• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Shattuck Labs Inc.

    5/21/25 6:14:16 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $STTK alert in real time by email
    DEFA14A 1 d47501ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    Shattuck Labs, Inc.

    (Name of Registrant as Specified in Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     
     


    LOGO

    P.O. BOX 8016, CARY, NC 27512-9903 Shattuck Labs, Inc. Annual Meeting of Stockholders Annual Meeting to be held live via the Internet at 11:30 AM Eastern Time on July 10, 2025. Please visit www.proxydocs.com/STTK for more details. You must register to attend and/or participate in the meeting online at www.proxydocs.com/STTK For a convenient way to view proxy materials, VOTE, and register to attend the meeting go to www.proxydocs.com/STTK To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet or by mail. This is not a ballot. You cannot use this notice to vote your shares. You may view the proxy materials at www.proxydocs.com/STTK or request a paper copy. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, the proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy materials or materials for future meetings, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before June 26, 2025. Unless requested, you will not otherwise receive a paper or e-mail copy. SEE REVERSE FOR FULL AGENDA Statement Meeting Materials: & Annual Notice Report of Meeting and Proxy Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to be Held on July 10, 2025. For Stockholders of Record as of May 14, 2025. To order paper materials for this and/or future stockholder meetings, use one of the following methods. Internet: www.investorelections.com/STTK Call: 1-866-648-8133 Email: [email protected] * If requesting materials by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting materials. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved


    LOGO

    Shattuck Labs, Inc. Annual Meeting of Stockholders The Board recommends that you vote your shares “FOR” each director nominee in Proposal 1 and “FOR” Proposal 2. PROPOSAL 1. To elect the three Class II director nominees to serve until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified: 1.01 Neil Gibson, Ph.D. 1.02 George Golumbeski, Ph.D. 1.03 Kate Sasser, Ph.D. 2. To ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025. To transact any other matters that may properly come before the Annual Meeting or any adjournments or postponements thereof. 

    Get the next $STTK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STTK

    DatePrice TargetRatingAnalyst
    3/17/2025$4.00Outperform
    Leerink Partners
    10/2/2024$8.00 → $2.00Buy → Neutral
    Citigroup
    10/2/2024Buy → Hold
    Needham
    10/1/2024Buy → Neutral
    H.C. Wainwright
    6/17/2024Buy → Neutral
    BTIG Research
    8/31/2022$12.00Buy
    BTIG Research
    6/1/2022$13.00Buy
    Citigroup
    5/2/2022$28.00Buy
    H.C. Wainwright
    More analyst ratings

    $STTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Redmile Group, Llc sold $166,714 worth of shares (133,371 units at $1.25), bought $166,714 worth of shares (133,371 units at $1.25), disposed of $1,283,610 worth of shares (1,026,888 units at $1.25) and acquired $1,283,610 worth of shares (1,026,888 units at $1.25) (SEC Form 4)

      4 - Shattuck Labs, Inc. (0001680367) (Issuer)

      12/6/24 9:00:15 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Schreiber Taylor bought $44,220 worth of shares (36,500 units at $1.21), increasing direct ownership by 106% to 71,002 units (SEC Form 4)

      4 - Shattuck Labs, Inc. (0001680367) (Issuer)

      10/8/24 6:05:12 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Brous Tyler bought $32,768 worth of shares (8,416 units at $3.89), increasing direct ownership by 4% to 238,088 units (SEC Form 4)

      4 - Shattuck Labs, Inc. (0001680367) (Issuer)

      7/1/24 6:30:02 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Technical Officer Shukla Abhinav A. covered exercise/tax liability with 2,261 shares, decreasing direct ownership by 3% to 73,536 units (SEC Form 4)

      4 - Shattuck Labs, Inc. (0001680367) (Issuer)

      1/28/25 6:13:29 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Business Officer Deyoung Casi covered exercise/tax liability with 2,297 shares, decreasing direct ownership by 3% to 81,465 units (SEC Form 4)

      4 - Shattuck Labs, Inc. (0001680367) (Issuer)

      1/28/25 6:08:41 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Pandite Arundathy N. covered exercise/tax liability with 3,211 shares, decreasing direct ownership by 2% to 206,265 units (SEC Form 4)

      4 - Shattuck Labs, Inc. (0001680367) (Issuer)

      1/28/25 6:04:53 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Shattuck Labs Inc.

      SC 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)

      12/6/24 9:03:38 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Shattuck Labs Inc.

      SC 13G/A - Shattuck Labs, Inc. (0001680367) (Subject)

      11/13/24 8:30:26 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Shattuck Labs Inc.

      SC 13G/A - Shattuck Labs, Inc. (0001680367) (Subject)

      11/12/24 5:01:20 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STTK
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Shattuck Labs Inc.

      DEFA14A - Shattuck Labs, Inc. (0001680367) (Filer)

      5/21/25 6:14:16 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Shattuck Labs Inc.

      DEF 14A - Shattuck Labs, Inc. (0001680367) (Filer)

      5/21/25 6:12:19 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Shattuck Labs Inc.

      10-Q - Shattuck Labs, Inc. (0001680367) (Filer)

      5/1/25 4:28:54 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STTK
    Leadership Updates

    Live Leadership Updates

    See more
    • Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors

      AUSTIN, TX and DURHAM, NC, March 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors, effective March 1, 2024. Both Dr. Siegall and Dr. Sasser are highly successful executives and scientific pioneers who bring valuable industry experience to Shattuck. "It is a pleasure to welcome Clay and Kate, esteemed industry leaders, to our Board of Directors," said Taylor Schre

      3/4/24 7:00:00 AM ET
      $IMNM
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023

      AUSTIN, TX and DURHAM, NC, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report its third-quarter 2023 financial results and provide a general business overview on Thursday, November 9, 2023. Title: Shattuck Labs Third-Quarter 2023 Earnings Call Speakers: Taylor Schreiber, CEO; Andrew Neill, CFO; Lini Pandite, CMO Date & Time: Thursday, November 9, 2023 at 8:00 a.m. ET Dial-in Details: Toll-Free Dial-In Number: 1 (888) 440-4368 To

      11/6/23 9:28:40 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs Announces Changes to its Board of Directors

      AUSTIN, TX and DURHAM, NC, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced the appointment of Dr. Carrie Brownstein, M.D., to its Board of Directors. Dr. Brownstein currently serves as the Chief Medical Officer at Cellectis. She will replace Josiah Hornblower, Shattuck's Chairman and founder, who is stepping down from the Board of Directors. George Golumbeski, Ph.D., has been appointed Chairman of the

      10/28/21 4:30:00 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STTK
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $STTK
    Financials

    Live finance-specific insights

    See more
    • Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

      – Company advances SL-325 program with an IND filing expected in the third quarter of 2025 – – Cash balance of approximately $60.9 million as of March 31, 2025, expected to fund operations into 2027 – AUSTIN, TX and DURHAM, NC, May 01, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2025 and provided recent business highlights. "All IND-enabling activities and regulatory interactions rem

      5/1/25 4:20:00 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

      AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present at and participate in one-on-one meetings at the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 2025. Conference DetailsFormat: Presentation and one-on-one meetingsPresenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive OfficerDate: April 9, 2025Time: 3:00 PM EDTWebcast link: HERE A

      4/2/25 5:00:00 PM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

      – Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn's and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class blocking antibody to DR3, the receptor for TL1A; data demonstrated favorable safety profile, full receptor occupancy, lack of DR3 agonism – – SL-325 advances toward Phase 1; on track for IND filing in the third quarter of 2025 – – Cash balance of approximately $73.0 million as of December 31, 2024, expected to fund operations into 2027 – AUSTIN, TX and DURHAM, NC, March 27, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneerin

      3/27/25 7:00:00 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

      – Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement in median overall survival compared to azacitidine monotherapy benchmarks; further development of SL-172154 discontinued –   – Prioritization to focus on SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A, intended for clinical development in inflammatory bowel disease (IBD); IND filing expected in Q3 2025 – – SL-172154 associated restructuring expected to extend cash runway into 2027 – – Company to host investor call today at 8:00 AM Eastern Time (ET) – AUSTIN, T

      10/1/24 6:30:00 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

      – Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had not yet been reached – – Observed 43% ORR in frontline TP53m AML patients, 33% CR/complete remission with incomplete hematologic recovery (CRi) and median overall survival had not yet been reached – – SL-172154 demonstrated a manageable interim safety profile in combination with AZA – – Focuses clinical development opportunity in HR-MDS and TP53m AML; these indications may offer the fastest path to potential approval; enrollment underway in randomized, controlled HR-MDS co

      6/14/24 6:00:00 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

      - Conference call and webcast to be held June 14, 2024 at 7:30 a.m. ET featuring lead investigator - AUSTIN, TX and DURHAM, NC, June 06, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that it will host an investor call for an interim safety and efficacy update from the Phase 1B dose expansion clinical trial of SL-172154 with AZA in HR-MDS and TP53m AML, being presented at the EHA 2024 Congress. The event will feature lead investigator, Dr. Naval G. Dave

      6/6/24 7:30:00 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Shattuck Labs with a new price target

      Leerink Partners initiated coverage of Shattuck Labs with a rating of Outperform and set a new price target of $4.00

      3/17/25 7:44:03 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs downgraded by Citigroup with a new price target

      Citigroup downgraded Shattuck Labs from Buy to Neutral and set a new price target of $2.00 from $8.00 previously

      10/2/24 7:58:39 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shattuck Labs downgraded by Needham

      Needham downgraded Shattuck Labs from Buy to Hold

      10/2/24 7:40:05 AM ET
      $STTK
      Biotechnology: Pharmaceutical Preparations
      Health Care